Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
Zacks.com on MSN2d
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
Pharmaceutical Technology on MSN3d
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
(RTTNews) - Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has secured global license to develop and sell LaNova's ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback